Category: Pelvic Floor & Prolapse
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
OnabotulinumtoxinA 200 U
vs Sacral neuromodulation (InterS |
refractory urgency urinary incontin |
OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence epi
mean difference, 0.63 episodes per day |
↑ |
PMC5399419
6 months |
| 📊 |
OnabotulinumtoxinA 200 U
vs Sacral neuromodulation (InterS |
refractory urgency urinary incontin |
OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46
mean difference, 8.1 on OAB-q SF symptom |
↑ |
PMC5399419
6 months |
| 📊 |
OnabotulinumtoxinA 200 U
vs Sacral neuromodulation (InterS |
refractory urgency urinary incontin |
Among participants completing at least 4 monthly diaries, 20% in the onabotulinumtoxinA group vs 4%
20% vs 4% complete resolution; 46% vs 26 |
↑ |
PMC5399419
6 months |
| 📊 |
OnabotulinumtoxinA 200 U
vs Sacral neuromodulation (InterS |
refractory urgency urinary incontin |
Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in th
35% vs 11%; risk difference, -23% Side effects: urinary tract infections 35%, multiple infections |
↓ |
PMC5399419
6 months |
| 📊 |
OnabotulinumtoxinA 200 U
vs Sacral neuromodulation (no cat |
refractory urgency urinary incontin |
In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, 4% at 3 m
8% at 1 month, 4% at 3 months, 2% at 6 m Side effects: intermittent self-catheterization 8% at 1 month, 4 |
↓ |
PMC5399419
6 months |
| 📊 |
Sacral neuromodulation
vs OnabotulinumtoxinA (no device) |
refractory urgency urinary incontin
Women |
In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed duri
3% (6 of 189 women) Side effects: device revision or removal 3% |
↓ |
PMC5399419
6 months |
OnabotulinumtoxinA 200 U resulted in a greater mean reduction in daily urgency incontinence episodes over 6 months compared to sacral neuromodulation (mean difference 0.63 episodes per day). (PMC5399419) A higher percentage of patients achieved complete resolution of urgency incontinence with onabotulinumtoxinA (20%) versus sacral neuromodulation (4%), and more patients had at least a 75% reduction in episodes (46% vs 26%). (PMC5399419) OnabotulinumtoxinA was associated with a significantly greater improvement in OAB symptom bother scores compared to sacral neuromodulation (mean difference 8.1, p=.002). (PMC5399419) Urinary tract infections were more common with onabotulinumtoxinA (35%) than with sacral neuromodulation (11%), with a risk difference of -23%. (PMC5399419) In the onabotulinumtoxinA group, 8% required intermittent self-catheterization at 1 month, decreasing to 2% at 6 months, while 3% of women in the sacral neuromodulation group had their device revised or removed within 6 months. (PMC5399419)